239 related articles for article (PubMed ID: 25402221)
1. Deferasirox effect on renal haemodynamic parameters in patients with transfusion-dependent β thalassaemia.
Piga A; Fracchia S; Lai ME; Cappellini MD; Hirschberg R; Habr D; Wegener A; Bouillaud E; Forni GL
Br J Haematol; 2015 Mar; 168(6):882-90. PubMed ID: 25402221
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.
Chandra J; Chaudhary H; Pemde H; Singh V; Dutta AK
Ann Trop Paediatr; 2011; 31(1):47-51. PubMed ID: 21262109
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox.
Naderi M; Sadeghi-Bojd S; Valeshabad AK; Jahantigh A; Alizadeh S; Dorgalaleh A; Tabibian S; Bamedi T
Pediatr Hematol Oncol; 2013 Nov; 30(8):748-54. PubMed ID: 24134694
[TBL] [Abstract][Full Text] [Related]
4. Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload.
Nolte F; Höchsmann B; Giagounidis A; Lübbert M; Platzbecker U; Haase D; Lück A; Gattermann N; Taupitz M; Baier M; Leismann O; Junkes A; Schumann C; Hofmann WK; Schrezenmeier H
Ann Hematol; 2013 Jan; 92(2):191-8. PubMed ID: 23073603
[TBL] [Abstract][Full Text] [Related]
5. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
6. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
7. Nephrolithiasis in beta thalassemia major patients treated with deferasirox: an advent or an adverse event? A single Greek center experience.
Efthimia V; Neokleous N; Agapidou A; Economou M; Vetsiou E; Teli A; Perifanis V
Ann Hematol; 2013 Jan; 92(2):263-5. PubMed ID: 22933235
[No Abstract] [Full Text] [Related]
8. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
9. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia.
Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC
Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901
[No Abstract] [Full Text] [Related]
10. Efficacy and safety of deferasirox in β-thalassemia major patients in Iran: a prospective study from a single referral center in Iran.
Alavi S; Ebadi M; Ghazizadeh F; Arzanian MT; Shamsian B; Abdollah Gorji F
Pediatr Hematol Oncol; 2014 Feb; 31(1):76-86. PubMed ID: 24383712
[TBL] [Abstract][Full Text] [Related]
11. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
Ladis V; Berdousi H; Gotsis E; Kattamis A
Br J Haematol; 2010 Dec; 151(5):504-8. PubMed ID: 20950401
[TBL] [Abstract][Full Text] [Related]
12. Effect of deferasirox on iron overload in patients with transfusion-dependent haemoglobinopathies.
Fragomeno C; Roccabruna E; D'Ascola DG
Blood Cells Mol Dis; 2015 Dec; 55(4):382-6. PubMed ID: 26460263
[TBL] [Abstract][Full Text] [Related]
13. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).
Angelucci E; Santini V; Di Tucci AA; Quaresmini G; Finelli C; Volpe A; Quarta G; Rivellini F; Sanpaolo G; Cilloni D; Salvi F; Caocci G; Molteni A; Vallisa D; Voso MT; Fenu S; Borin L; Latte G; Alimena G; Storti S; Piciocchi A; Fazi P; Vignetti M; Tura S
Eur J Haematol; 2014 Jun; 92(6):527-36. PubMed ID: 24580147
[TBL] [Abstract][Full Text] [Related]
14. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of deferasirox in myelodysplastic syndromes.
Breccia M; Alimena G
Ann Hematol; 2013 Jul; 92(7):863-70. PubMed ID: 23417759
[TBL] [Abstract][Full Text] [Related]
16. Deferasirox for managing iron overload in people with thalassaemia.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Motschall E; Niemeyer CM; Bassler D
Cochrane Database Syst Rev; 2012 Feb; (2):CD007476. PubMed ID: 22336831
[TBL] [Abstract][Full Text] [Related]
17. Cardiac iron load and function in transfused patients treated with deferasirox (the MILE study).
Ho PJ; Tay L; Teo J; Marlton P; Grigg A; St Pierre T; Brown G; Badcock CA; Traficante R; Gervasio OL; Bowden DK
Eur J Haematol; 2017 Feb; 98(2):97-105. PubMed ID: 27537786
[TBL] [Abstract][Full Text] [Related]
18. GFR in Patients with β-Thalassemia Major.
Milo G; Feige Gross Nevo R; Pazgal I; Gafter-Gvili A; Shpilberg O; Gafter U; Erman A; Stark P
Clin J Am Soc Nephrol; 2015 Aug; 10(8):1350-6. PubMed ID: 25964308
[TBL] [Abstract][Full Text] [Related]
19. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease.
Vichinsky E; Onyekwere O; Porter J; Swerdlow P; Eckman J; Lane P; Files B; Hassell K; Kelly P; Wilson F; Bernaudin F; Forni GL; Okpala I; Ressayre-Djaffer C; Alberti D; Holland J; Marks P; Fung E; Fischer R; Mueller BU; Coates T;
Br J Haematol; 2007 Feb; 136(3):501-8. PubMed ID: 17233848
[TBL] [Abstract][Full Text] [Related]
20. Deferasirox for managing transfusional iron overload in people with sickle cell disease.
Meerpohl JJ; Antes G; Rücker G; Fleeman N; Niemeyer C; Bassler D
Cochrane Database Syst Rev; 2010 Aug; (8):CD007477. PubMed ID: 20687088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]